Compare Neurocrine Biosciences Inc (NBIX) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Progressive Corp — how do they compare? Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B), while Progressive Corp trades at $217.43 (market cap $126.95B). The key difference: Progressive Corp is far larger — about 8.8× Neurocrine Biosciences Inc's market cap, and Progressive Corp pays a 0.18% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Progressive Corp for 81 Days on average.
| NBIX | PGR | |
|---|---|---|
Market Cap | $14.36B | $126.95B |
Volume | 1,237,180 | 2,749,438 |
Sector | Health | Financials |
52-Week High | $185.50 | $242.16 |
52-Week Low | $123.10 | $190.40 |
Typical Hold Time | 23 Days | 81 Days |
Enterprise Value | $14.37B | $135.16B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Progressive Corporation (PGR) trades at $217.43, up 1.55% with a bullish technical outlook supported by moving averages and strong institutional interest. The company demonstrates robust fundamentals with revenue growing from $49.6B in 2022 to $87.6B in 2025, net income reaching $11.3B, and impressive profitability metrics including 34.94% ROE. Recent earnings show mixed results with Q2 2026 beating expectations while Q1 2026 missed, with Q3 2026 results pending.
The stock presents a compelling value opportunity with a P/E of 10.97 and positive analyst sentiment (38.1% buy ratings), though competitive pressures in auto insurance and potential market volatility pose risks. With a consensus price target of $222.23 offering modest upside, PGR remains well-positioned for long-term growth given its operational strength and dividend consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
